HIV treatment for patients: NMN shows promise in reducing CD4+ T cell activation

Renewed hope for HIV patients as NMN shows promise in reducing CD4+ T-cell activation – Current research shows the potential of nicotinamide mononucleotide (NMN) as a promising therapeutic approach for the treatment of HIV/AIDS.

Hope for HIV patients as NMN shows promise in reducing CD4+ T cell activation
Hope for HIV patients as NMN shows promise in reducing CD4+ T cell activation

A current study published in the renowned journal diary The lancet has brought to light a potentially groundbreaking development in the field of HIV/AIDS treatment. The study, conducted by a team of dedicated researchers, examined the effects of nicotinamide mononucleotide (NMN), a natural precursor to nicotinamide adenine dinucleotide (NAD+), on human immunodeficiency virus (HIV) infection. The results of this study offer a ray of hope for people living with HIV/AIDS as they suggest that NMN may hold promise as a novel therapeutic approach.

CD4+ T cells, a crucial component of the immune system, serve as primary targets for HIV. As the virus wreaks havoc on these cells, the immune system’s ability to fight off infections decreases significantly. The study found that NMN treatment was effective in reducing activation of CD4+ T cells, a crucial step in the HIV replication cycle. By hindering the activation of CD4+ T cells, NMN potentially interferes with the virus’s ability to multiply and spread in the body.

The researchers delved deeper into the underlying mechanism of NMN’s inhibitory effect on CD4+ T cell activation. They discovered that NMN treatment increased intracellular NAD+ levels in CD4+ T cells. NAD+, a versatile coenzyme, plays a central role in various cellular processes, including DNA repair and energy production. The researchers assume that the increased NAD+ levels resulting from NMN treatment could strengthen the defenses of CD4+ T cells against HIV infection.

Further investigations by the study team revealed an additional positive effect of NMN treatment. They observed that NMN effectively downregulates the expression of late T cell activation markers, molecules that decorate the surface of activated T cells. This suppression of activation marker expression enhances the potential of NMN to impede activation of CD4+ T cells and render them less susceptible to HIV infection.

While the study provides compelling evidence for the therapeutic potential of NMN in HIV/AIDS treatment, the researchers cautiously acknowledge that further research is needed to substantiate these findings. They emphasize the importance of conducting larger clinical trials to definitively establish the safety and effectiveness of NMN in human populations.

Nevertheless, the promising results of this study offer a ray of hope for people struggling with HIV/AIDS. The ability of NMN to reduce CD4+ T cell activation and suppress expression of activation markers represents a compelling opportunity to develop a novel treatment strategy that could significantly impact the lives of those affected by this devastating disease. As research progresses, we eagerly await the validation of these results and the subsequent translation of NMN into an effective therapeutic tool for HIV/AIDS treatment.

Summary of the study


  • NMN treatment reduced CD4+ T cell activation in vitro and in vivo.
  • The effect of NMN on CD4+ T cell activation was associated with increased intracellular NAD+ levels.
  • NMN treatment had no significant cytotoxic effects.


The results of this study suggest that NMN may have potential as a new treatment for HIV/AIDS by reducing CD4+ T cell activation. However, further research is needed to confirm these results.


[1] Wang, S., et al. (2023). Nicotinamide mononucleotide influences HIV-1 infection by modulating immune activation in T lymphocytes and humanized mice. The lancet

You can continue to find more articles like this on our website. And please use our comments section, we would love to hear from you.

Emma James

Emma James is a USTimesPost U.S. News Reporter based in London. His focus is on U.S. politics and the environment. He has covered climate change extensively, as well as healthcare and crime. Emma James joined USTimesPost in 2023 from the Daily Express and previously worked for Chemist and Druggist and the Jewish Chronicle. He is a graduate of Cambridge University. Languages: English. You can get in touch with me by emailing

Related Articles

Back to top button